Clear Search sequence regions


  • angiogenesis (1)
  • b cells (1)
  • cancer (2)
  • CCL3 (1)
  • CX3CL1 (1)
  • CXCR7 (1)
  • fibroblasts (1)
  • humans (1)
  • macrophages (14)
  • prognosis (2)
  • receptor (1)
  • research (1)
  • stromal cells (1)
  • t cells (1)
  • tumor metastasis (2)
  • Sizes of these terms reflect their relevance to your search.

    Tumor microenvironment (TME) consists of a dynamic network of non-tumoral stromal cells, including cancer-associated fibroblasts, endothelial cells, tumor-associated macrophages (TAMs), B and T cells. In the TME, TAMs support tumor initiation, progression, invasion and metastasis by promoting angiogenesis and immunosuppression of the tumor cells. There is close crosstalk between TAMs and tumor cells. Notably, chemokines are a significant messenger mediating the crosstalk between tumor cells and TAMs. TAMs can promote tumor progression via secretion of chemokines. Various chemokines secreted by tumors are involved in the generation and polarization of TAMs, the infiltration of TAMs in tumors, and the development of TAMs' suppressive function. This paper reviews CCL2-CCR2, CCL3/5-CCR5, CCL15-CCR1, CCL18-CCR8, CX3CL1/CCL26-CX3CR1, CXCL8-CXCR1/2, CXCL12-CXCR4/CXCR7 signaling pathways, their role in the recruitment, polarization and exertion of TAMs, and their correlation with tumor development, metastasis and prognosis. Furthermore, we present the current research progress on modulating the effects of TAMs with chemokine antagonists and discuss the prospects and potential challenges of using chemokine antagonists as therapeutic tools for cancer treatment. The TAMs targeting by chemokine receptor antagonists in combination with chemotherapy drugs, immune checkpoint inhibitors or radiotherapy appears to be a promising approach. © 2022. The Author(s).

    Citation

    Rui Qin, Weihong Ren, Guoqi Ya, Bei Wang, Jiao He, Shaoxin Ren, Lu Jiang, Shuo Zhao. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clinical and experimental medicine. 2023 Sep;23(5):1359-1373

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36173487

    View Full Text